Preview

 Пульмонология

Расширенный поиск

Идиопатический легочный фиброз

https://doi.org/10.18093/0869-0189-2015-25-5-600-612

Полный текст:

Аннотация

Идиопатический легочный фиброз (ИЛФ) встречается преимущественно у лиц среднего и пожилого возраста, являясь наиболее частым заболеванием из группы интерстициальных заболеваний легких. На протяжении последнего десятилетия произошли значительные изменения в подходах не только к диагностике, но и в определении ИЛФ. В данной статье представлены современные данные об эпидемиологии данного заболевания, приведены результаты новых исследований о патогенезе и основные подходы к диагностике заболевания. Кроме того, представлены новые данные о течении ИЛФ и наиболее часто встречающихся сопутствующих заболеваниях.

Об авторе

С. Н. Авдеев
ФГБУ «НИИ пульмонологии» ФМБА России: 105077, Москва, ул. 11&я Парковая, 32, корп. 4
Россия

д. м. н., профессор, руководитель клинического отдела ФГБУ «НИИ пульмонологии» ФМБА России, тел. / факс: (495) 4655264



Список литературы

1. Raghu G., Collard H.R., Egan J.J. et al. An official ATS /ERS / JRS / ALAT statement: idiopathic pulmonary fibrosis; evidencebased guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 2011; 183: 788–824.

2. Raghu G., Rochwerg B., Zhang Y. et al. An Official ATS /ERS / JRS / ALAT Clinical Practice Guideline: Treatment of idiopathic pulmonary fibrosis: Executive summary. An update of the 2011 Clinical Practice Guideline. Am. J. Respir. Crit. Care Med. 2015; 192: e3–e19.

3. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment; international consensus statement. Am. J. Respir. Crit. Care Med. 2000; 161: 646–664.

4. Ryu J.H., Moua T., Daniels C.E. et al. Idiopathic pulmonary fibrosis: Evolving concepts. Mayo. Clin. Proc. 2014; 89: 1130–1142.

5. Travis W.D., Costabe U., Hansell D.M. et al. An official American Thoracic Society / European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am. J. Respir. Crit. Care Med. 2013; 188: 733–748.

6. Collard H.R., King T.E. Demystifying idiopathic interstitial pneumonia. Arch. Intern. Med. 2003; 163: 17–29.

7. American Thoracic Society. European Respiratory Society. American Thoracic Society / European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am. J. Respir. Crit. Care Med. 2002; 165: 277–304.

8. Katzenstein A.L., Myers J.L. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am. J. Respir. Crit. Care Med. 1998; 157: 1301–1315.

9. Richeldi L., Sperb Rubin A., Avdeev S. et al. Idiopathic pulmonary fibrosis in BRIC countries: the cases of Brazil, Russia, India, and China. BMC Medicine. 2015; 13: 237.

10. Rindfleisch G.E. Ueber cirrhosis cystica pulmonum. Zentralbl. Pathol. 1897; 8: 864–865.

11. Илькович М.М., Новикова Л.Н., Королева М.Г. Идиопатический фиброзирующий альвеолит: противоречия в современных представлениях. Пульмонология. 2003; 3: 98–101. / Il'kovich M.M., Novikova L.N., Koroleva M.G. Idiopathic pulmonary fibrosis: controversies in the current view. Pul'monologiya. 2003; 3: 98–101 (in Russian).

12. Илькович М.М., Новикова Л.Н., Сперанская А.А. Идиопатический фиброзирующий альвеолит: современные представления. Consilium Medicum. 2009; 11: 24–29. / Il'kovich M.M., Novikova L.N., Speranskaya A.A. Idiopathic pulmonary fibrosis: the current view. Consilium Medicum. 2009; 11: 24–29 (in Russian)

13. Bjoraker J.A., Ryu J.H., Edwin M.K. et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 1998; 157: 199–203.

14. Nagai S., Kitaichi M., Itoh H. et al. Idiopathic nonspecific interstitial pneumonia / fibrosis: comparison with idiopathic pulmonary fibrosis and BOOP. Eur. Respir. J. 1998; 12: 1010–1019.

15. Daniil Z.D., Gilchrist F.C., Nicholson A.G. et al. A histologic pattern of nonspecific interstitial pneumonia is associated with a better prognosis than usual interstitial pneumonia in patients with cryptogenic fibrosing alveolitis. Am. J. Respir. Crit. Care Med. 1999; 160: 899–905.

16. Fernández Pérez E.R., Daniels C.E., Schroeder D.R. et al. Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: a populationbased study. Chest. 2010; 137: 129–137.

17. Raghu G., Weycker D., Edelsberg J. et al. Incidence and prevalence of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2006; 174: 810–816.

18. Douglas W.W., Ryu J.H., Schroeder D.R. Idiopathic pulmonary fibrosis: impact of oxygen and colchicine, prednisone, or no therapy on survival. Am. J. Respir. Crit. Care Med. 2000; 161: 1172–1178.

19. King T.E., Tooze J.A., Schwarz M.I. et al. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am. J. Respir. Crit. Care Med. 2001; 164: 1171–1181.

20. Nadrous H.F., Myers J.L., Decker P.A., Ryu J.H. Idiopathic pulmonary fibrosis in patients younger than 50 years. Mayo. Clin. Proc. 2005; 80: 37–40.

21. Selman M., King T.E., Pardo A. American Thoracic Society; European Respiratory Society; American College of Chest Physicians. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann. Intern. Med. 2001; 134: 136–151.

22. du Bois R.M. Strategies for treating idiopathic pulmonary fibrosis. Nat. Rev. Drug. Discov. 2010; 9: 129–140.

23. Allam J.S., Limper A.H. Idiopathic pulmonary fibrosis: is it a familial disease? Curr. Opin. Pulm. Med. 2006; 12:312–317.

24. Steele M.P., Speer M.C., Loyd J.E. et al. Clinical and pathologic features of familial interstitial pneumonia. Am. J. Respir. Crit. Care Med. 2005; 172: 1146–1152.

25. Lee H.L., Ryu J.H., Wittmer M.H. et al. Familial idiopathic pulmonary fibrosis: clinical features and outcome. Chest. 2005; 127: 2034–2041.

26. Wahidi M.M., Speer M.C., Steele M.P. et al. Familial pulmonary fibrosis in the United States. Chest. 2002; 121: 30.

27. Taskar V., Coultas D. Exposures and idiopathic lung disease. Semin. Respir. Crit. Care Med. 2008; 29: 670–679.

28. Blackwell T.S., Tager A.M., Borok Z. et al. Future directions in idiopathic pulmonary fibrosis research: an NHLBI work shop report. Am. J. Respir. Crit. Care Med. 2014; 189:214–222.

29. Rosas I.O., Kottman R.M., Sime P.J. New light is shed on the enigmatic origin of the lung myofibroblast. Am. J. Respir. Crit. Care Med. 2013; 188: 765–766.

30. Phan S.H. Genesis of the myofibroblast in lung injury and fibrosis. Proc. Am. Thorac. Soc. 2012; 9: 148–152.

31. Xia H., Bodempudi V., Benyumov A. et al. Identification of a celloforigin for fibroblasts comprising the fibrotic reticulum in idiopathic pulmonary fibrosis Am. J. Pathol. 2014; 184: 1369–1383.

32. Noble P.W., Barkauskas C.E., Jiang D. Pulmonary fibrosis: patterns and perpetrators. J. Clin. Invest. 2012; 122:2756–2762.

33. Maher T.M. Beyond the diagnosis of idiopathic pulmonary fibrosis: the growing role of systems biology and stratified medicine. Curr. Opin. Pulm. Med. 2013; 19: 460–465.

34. Shimbori C., Gauldie J., Kolb M. Extracellular matrix microenvironment contributes actively to pulmonary fibrosis. Curr. Opin. Pulm. Med. 2013; 19: 446–452.

35. Alder J.K., Chen J.J., Lancaster L. et al. Short telomeres are a risk factor for idiopathic pulmonary fibrosis. Proc. Natl. Acad. Sci. 2008; 105: 13051–13056.

36. Chilosi M., Carloni A., Rossi A., Poletti V. Premature lungaging and cellular senescence in the pathogenesis of idiopathic pulmonary fibrosis and COPD / emphysema. Transl. Res. 2013; 162: 156–173.

37. Leslie K.O. Idiopathic pulmonary fibrosis may be a disease of recurrent, tractional injury to the periphery of the aging lung: a unifying hypothesis regarding etiology and pathogen esis. Arch. Pathol. Lab. Med. 2012; 136: 591–600.

38. Seibold M.A., Wise A.L., Speer M.C. et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N. Engl. J. Med. 2011; 364: 1503–1512.

39. Peljto A.L., Zhang Y., Fingerlin T.E. et al. Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. JAMA. 2013; 309: 2232–2239.

40. Armanios M.Y., Chen J.J., Cogan J.D. et al. Telomerase mutations in families with idiopathic pulmonary fibrosis. N. Engl. J. Med. 2007; 356: 1317–1326.

41. Cronkhite J.T., Xing C., Raghu G. et al. Telomere shorten ing in familial and sporadic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2008; 178: 729–737.

42. Liu T., Ullenbruch M., Young Choi Y. et al. Telomerase and telomere length in pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 2013; 49: 260–268.

43. Thomas A.Q., Lane K., Phillips J. et al. Heterozygosity for a surfactant protein C gene mutation associated with usual interstitial pneumonitis and cellular nonspecific interstitial pneumonitis in one kindred. Am. J. Respir. Crit. Care Med. 2002; 165: 1322–1328.

44. Wang Y., Kuan P.J., Xing C. et al. Genetic defects in surfactant protein A2 are associated with pulmonary fibrosis and lung cancer. Am. J. Hum. Genet. 2009; 84: 52–59.

45. Behr J., Ryu J.H. Pulmonary hypertension in interstitial lung disease. Eur. Respir. J. 2008; 31: 1357–1367.

46. Nathan S.D., Noble P.W., Tuder R.M. Idiopathic pulmonary fibrosis and pulmonary hypertension: connecting the dots. Am. J. Respir. Crit. Care Med. 2007; 175: 875–880.

47. Zhang Y., Kaminski N. Biomarkers in idiopathic pulmonary fibrosis. Curr. Opin. Pulm. Med. 2012; 18: 441–446.

48. Vij R., Noth I. Peripheral blood biomarkers in idiopathic pulmonary fibrosis. Transl. Res. 2012; 159: 218–227.

49. Tzouvelekis A., Kouliatsis G., Anevlavis S., Bouros D. Serum biomarkers in interstitial lung diseases. Respir. Res. 2005; 6: 78.

50. Prasse A., MüllerQuernheim J. Noninvasive biomarkers in pulmonary fibrosis. Respirology. 2009; 14: 788–795.

51. Авдеева О.Е., Лебедин Ю.С., Авдеев С.Н. и др. Гликозилированный муцинантиген 3EG5 – сывороточный маркер активности и тяжести при интерстициальных заболеваниях легких. Пульмонология. 1998; 2: 22–27. / Avdeeva O.E., Lebedin Yu.S., Avdeev S.N. et al. 3EG5 glycosilazed mucin antigen is a serum biomarker of activity and severity of interstitial lung disease. Pul'monologiya. 1998; 2: 22–27 (in Russian).

52. Silva C.I., Müller N.L. Idiopathic interstitial pneumonias. J. Thorac. Imaging. 2009; 24: 260–273.

53. Lynch D.A., Godwin J.D., Safrin S. et al. Highresolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. Am. J. Respir. Crit. Care Med. 2005; 172: 488–493.

54. Arakawa H., Honma K. Honeycomb lung: history and current concepts. Am. J. Roentgenol. 2011; 196: 773–782.

55. Martinez F.J., Flaherty K. Pulmonary function testing in idiopathic interstitial pneumonias. Proc. Am. Thorac. Soc. 2006; 3: 315–321.

56. Cottin V., Nunes H., Brillet P.Y. et al. Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur. Respir. J. 2005; 26: 586–593.

57. Jankowich M.D., Rounds S.I. Combined pulmonary fibrosis and emphysema syndrome: a review. Chest. 2012; 141: 222–231.

58. Ryerson C.J., Hartman T., Elicker B.M. et al. Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis. Chest. 2013; 144: 234–240.

59. Trahan S., Hanak V., Ryu J.H., Myers J.L. Role of surgical lung biopsy in separating chronic hypersensitivity pneumonia from usual interstitial pneumonia / idiopathic pulmonary fibrosis: analysis of 31 biopsies from 15 patients. Chest. 2008; 134: 126–132.

60. Misumi S., Lynch D.A. Idiopathic pulmonary fibrosis / usual interstitial pneumonia: imaging diagnosis, spectrum of abnormalities, and temporal progression. Proc. Am. Thorac. Soc. 2006; 3: 307–314.

61. Ryu J.H., Daniels C.E., Hartman T.E., Yi E.S. Diagnosis of interstitial lung diseases. Mayo. Clin. Proc. 2007; 82: 976–986.

62. Leslie K.O., Gruden J.F., Parish J.M., Scholand M.B. Transbronchial biopsy interpretation in the patient with diffuse parenchymal lung disease. Arch. Pathol. Lab. Med. 2007; 131: 407–423.

63. Ohshimo S., Bonella F., Cui A. et al. Significance of bronchoalveolar lavage for the diagnosis of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2009; 179: 1043–1047.

64. Casoni G.L., Tomassetti S., Cavazza A. et al. Transbronchial lung cryobiopsy in the diagnosis of fibrotic interstitial lung diseases. PLoS One. 2014; 9: e86716.

65. Maldonado F., Ryu J.H. Surgical biopsy for diffuse parenchymal lung diseases: are we causing more harm than good? J. Bronchology Interv. Pulmonol. 2009; 16: 227–228.

66. Riley D.J., Costanzo E.J. Surgical biopsy: its appropriate ness in diagnosing interstitial lung disease. Curr. Opin. Pulm. Med. 2006; 12: 331–336.

67. Sharma S. Diagnosing idiopathic pulmonary fibrosis: to biopsy or not to biopsy [editorial]. Curr. Opin. Pulm. Med. 2012; 18: 528–529.

68. Utz J.P., Ryu J.H., Douglas W.W. et al. High shortterm mortality following lung biopsy for usual interstitial pneumonia. Eur. Respir. J. 2001; 17: 175–179.

69. Park J.H., Kim D.K., Kim D.S. et al. Mortality and risk factors for surgical lung biopsy in patients with idiopathic interstitial pneumonia. Eur. J. Cardiothorac. Surg. 2007; 31: 1115–1119.

70. Flaherty K.R., King T.E., Raghu G. et al. Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis? Am. J. Respir. Crit. Care Med. 2004; 170: 904–910.

71. Smith M., Dalurzo M., Panse P. et al. Usual interstitial pneumoniapattern fibrosis in surgical lung biopsies: clinical, radiological and histopathological clues to aetiology. J. Clin. Pathol. 2013; 66: 896–903.

72. Ley B., Collard H.R., King T.E. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2011; 183: 431–440.

73. Selman M., Carrillo G., Estrada A. et al. Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and geneexpression pattern. PLoS One. 2007; 2: e482.

74. Wells A.U., Desai S.R., Rubens M.B. et al. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am. J. Respir. Crit. Care Med. 2003; 167: 962–969.

75. Ley B., Ryerson C.J., Vittinghoff E. et al. A multidimen sional index and staging system for idiopathic pulmonary fibrosis. Ann. Intern. Med. 2012; 156: 684–691.

76. du Bois R.M., Weycker D., Albera C. et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2011; 184:459–466.

77. Daniels C.E., Yi E.S., Ryu J.H. Autopsy findings in 42 consecutive patients with idiopathic pulmonary fibrosis. Eur. Respir. J. 2008; 32: 170–174.

78. Panos R.J., Mortenson R.L., Niccoli S.A., King T.E. Clinical deterioration in patients with idiopathic pulmonary fibrosis: causes and assessment. Am. J. Med. 1990; 88:396–404.

79. Spagnolo P., Wells A.U., Collard H.R. Pharmacological treatment of idiopathic pulmonary fibrosis: an update. Drug Discovery Today; 2015. http://dx.doi.org/10.1016/ j.drud'is.2015.01.001

80. Wolters P.J., Collard H.R., Jones K.D. Pathogenesis of idiopathic pulmonary fibrosis. Ann. Rev. Pathol. 2014; 9: 157–179.

81. Richeldi L., Davies H.R., Ferrara G. et al. Corticosteroids for idiopathic pulmonary fibrosis. Cochrane Database Syst. Rev. 2003; 3: CD002880.

82. Richeldi L., Davies H.R., Spagnolo P. et al. Corticosteroids for idiopathic pulmonary fibrosis. Cochrane Database Syst. Rev. 2010; 2: CD002880.

83. Raghu G., Anstrom K.J., King T.E. et al. Idiopathic Pulmonary Fibrosis Clinical Research Network. Prednisone, azathioprine, and Nacetylcysteine for pulmonary fibrosis. N. Engl. J. Med. 2012; 366: 1968–1977.

84. Spagnolo P., Del Giovane C., Luppi F. et al. Nonsteroid agents for idiopathic pulmonary fibrosis. Cochrane Database Syst. Rev. 2010; 9: CD003134.

85. King T.E., Pardo A., Selman M. Idiopathic pulmonary fibrosis. Lancet 2011; 378: 1949–1961.

86. Gauldie J., Kolb M. Animal models of pulmonary fibrosis: how far from effective reality? Am. J. Physiol. Lung Cell Mol. Physiol. 2008; 294: L151.

87. Noble P.W., Richeldi L., Kaminski N. End of an ERA: lessons from negative clinical trials in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2011; 184: 4–5.

88. Ziesche R., Hofbauer E., Wittmann K. et al. A preliminary study of longterm treatment with interferon gamma1b and lowdose prednisolone in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 1999; 341: 1264–1269.

89. Raghu G., Brown K.K., Bradford W.Z. et al. A placebocon trolled trial of interferon gamma1b in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 2004; 350: 125–133.

90. King T.E., Albera C., Bradford W.Z. et al. Effect of interfer on gamma1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebocontrolled trial. Lancet. 2009; 374: 222–228.

91. Luppi F., Losi M., D’Amico R. et al. Endogenous blood maximal interferongamma production may predict response to interferongamma 1beta treatment in patients with idiopathic pulmonary fibrosis. Sarcoidosis Vasc. Diffuse Lung Dis. 2009; 26: 64–68.

92. Casoni G.L., Chilosi M., Romagnoli M. et al. Another «chance» for interferon gamma1b? Sarcoidosis Vasc. Diffuse Lung Dis. 2011; 28: 79–80.

93. King T.E., Behr J., Brown K.K. et al. BUILD1: a randomized placebocontrolled trial of bosentan in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2008; 177: 75–81.

94. King T.E., Brown K.K., Raghu G. et al. BUILD3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2011; 184: 92–99.

95. Raghu G., Brown K.K., Costabel U. et al. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebocontrolled trial. Am. J. Respir. Crit. Care Med. 2008; 178: 948–955.

96. Daniels C.E., Lasky J.A., Limper A.H. et al. Imatinib treatment for idiopathic pulmonary fibrosis: Randomized place bocontrolled trial results. Am. J. Respir. Crit. Care Med. 2010; 181: 604–610.

97. Richeldi L., Brown K.K., Costabel U. et al. The oral triplekinase inhibitor BIBF 1120 reduces decline in lung function in patients with idiopathic pulmonary fibrosis (IPF): results from the tomorrow study. Am. J. Respir. Crit. Care Med. 2011; 183: A5303.

98. Richeldi L., Costabel U., Selman M. et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2011; 365: 1079–1087.

99. Richeldi L., du Bois R.M., Raghu G. et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014; 370: 2071–2082.

100. Raghu G., Johnson W.C., Lockhart D. et al. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: Results of a prospective, openlabel phase II study. Am. J. Respir. Crit. Care Med. 1999; 159: 1061–1069.

101. Horita A., Nukiwa T., Tsuboi E. et al. Doubleblind, place bocontrolled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2005; 171: 1040–1047.

102. Taniguchi H., Ebina M., Kondoh Y. et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur. Respir. J. 2010; 35: 821–829.

103. Noble P.W., Albera C., Bradford W.Z. et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011; 377: 1760–1769.

104. King T.E., Bradford W.Z., CastroBernardini S. et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014; 370: 2083–2092.

105. Demedts M., Behr J., Buhl R. et al. Highdose acetylcys teine in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2005; 353: 2229–2242.

106. Martinez F.J., de Andrade J.A., Anstrom K.J. et al. Randomized trial of Ncetylcysteine in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014; 370: 2093–2101.

107. Kubo H., Nakayama K., Yanai M. et al. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest. 2005; 128: 1475–1482.

108. Noth I., Anstrom K.J., Calvert S.B. et al. A placebocon trolled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2012; 186: 88–95.

109. De Vries J., Kessels B.L., Drent M. Quality of life of idiopathic pulmonary fibrosis patients. Eur. Respir. J. 2001; 17: 954–961.

110. Ries A.L., Bauldoff G.S., Carlin B.W. et al. Pulmonary reha bilitation: Joint ACCP/AACVPR evidencebased clinical practice guidelines. Chest. 2007; 131 (Suppl. 5): 4S–42S.

111. Douglas W.W., Ryu J.H., Schroeder D.R. Idiopathic pulmonary fibrosis: Impact of oxygen and colchicine, prednisone, or no therapy on survival. Am. J. Respir. Crit. Care Med. 2000; 161: 1172–1178.

112. Nici L., Donner C., Wouters E. et al. American Thoracic Society / European Respiratory Society statement on pulmonary rehabilitation. Am. J. Respir. Crit. Care Med. 2006; 173: 1390–1413.

113. Spruit M.A., Janssen D.J., Franssen F.M. et al. Rehabilitation and palliative care in lung fibrosis. Respirology. 2009; 14: 781–787.

114. Holland A.E., Hill C.J., Conron M. et al. Short termimprovement in exercise capacity and symptoms following exercise training in interstitial lung disease. Thorax. 2008; 63: 549–554.

115. Saydain G., Islam A., Afessa B. et al. Outcome of patients with idiopathic pulmonary fibrosis admitted to the intensive care unit. Am. J. Respir. Crit. Care Med. 2002; 166: 839–842.

116. Stern J.B., Mal H., Groussard O. et al. Prognosis of patients with advanced idiopathic pulmonary fibrosis requiring mechanical ventilation for acute respiratory failure. Chest. 2001; 120: 213–219.

117. Mallick S. Outcome of patients with idiopathic pulmonary fibrosis (IPF) ventilated in intensive care unit. Respir. Med. 2008; 102: 1355–1359.

118. Beckmann A., Benk C., Beyersdorf F. et al. Position article for the use of extracorporeal life support in adult patients. Eur. J. Cardiothorac. Surg. 2011; 40: 676–680.

119. Allen S., Raut S., Woollard J. et al. Low dose diamorphine reduces breathlessness without causing a fall in oxygen saturation in elderly patients with endstage idiopathic pulmonary fibrosis. Palliat. Med. 2005; 19: 128–130.

120. Ryerson C.J., Berkeley J., CarrieriKohlman V.L. et al. Depression and functional status are strongly associated with dyspnea in interstitial lung disease. Chest. 2011; 139: 609–616.

121. Trulock E.P., Edwards L.B., Taylor D.O. et al. The Registry of the International Society for Heart and Lung Transplantation: twentieth official adult lung and heartlung transplant report2003. J. Heart Lung. Transplant. 2003; 22: 625–635.

122. Yusen R.D., Shearon T.H., Qian Y. et al. Lung transplantation in the United States, 19992008. Am. J. Transplant. 2010; 10: 1047–1068.

123. Mason D.P., Brizzio M.E., Alster J.M. et al. Lung transplantation for idiopathic pulmonary fibrosis. Ann. Thorac. Surg. 2007; 84: 1121–1128.

124. Keating D., Levvey B., Kotsimbos T. et al. Lung transplantation in pulmonary fibrosis: challenging early outcomes counterbalanced by surprisingly good outcomes beyond 15 years. Transplant. Proc. 2009; 41: 289–291.

125. Algar F.J., Espinosa D., Moreno P. et al. Results of lung transplantation in idiopathic pulmonary fibrosis patients. Transplant. Proc. 2010; 42: 3211–3213.


Для цитирования:


Авдеев С.Н. Идиопатический легочный фиброз.  Пульмонология. 2015;25(5):600-612. https://doi.org/10.18093/0869-0189-2015-25-5-600-612

For citation:


Avdeev S.N. Idiopathic pulmonary fibrosis. Russian Pulmonology. 2015;25(5):600-612. (In Russ.) https://doi.org/10.18093/0869-0189-2015-25-5-600-612

Просмотров: 2093


ISSN 0869-0189 (Print)
ISSN 2541-9617 (Online)